Caribou Biosciences, Inc.
Most recent annual filing: 2026-03-05
Pipeline (4 active programs)
CB-011
Technology platforms
chRDNA
CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology using hybrid guides containing both RNA and DNA for editing genomic DNA; enables high-specificity multiplex genome editing for ex vivo allogeneic CAR-T cell therapies; focus areas include oncology and autoimmune diseases
Discontinued (2)
- vispa-cel — Lupus · discontinued GALLOP phase 1 trial prior to dosing the first patient as part of strategic pipeline prioritization
- CB-012 — Relapsed/Refractory Acute Myeloid Leukemia · discontinued AMpLify phase 1 clinical trial as additional data would be needed to advance this program; license agreement with MSKCC terminated
Biotech Distilled coverage (2)
- 2026-05-08 UPDATE: Caribou Biosciences (CRBU) - The FDA Said Yes, The Bank Account Said “About That...” 🔒 Paid
- 2026-04-17 Caribou Biosciences (CRBU) - Scientific Deep Dive for Vispa-cel and CB-011 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.